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Altitude exposure and increased heart rate: the role of the parasympathetic nervous 
system 
 
Julia Attias, Julie Bieles, Philip Carvil, Charles Laing, Fiona Lewis, Oihane Jaka, Katie O'Brien and 
Prashant Ruchaya 
 
Elevated heart rate (HR) has been demonstrated in response to acute hypoxia exposure, which 
is reportedly due to sympathetic nervous system activation (SNS) and concurrent withdrawal 
of parasympathetic nervous system activity (PSNS) (Koller et al, 1988). Although it is also 
known that this increased HR persists with chronic hypoxia exposure (Vogel et al, 1974), the 
mechanisms are less clear.   
The authors discuss the conflicting research that presents itself within this area of research. 
Studies have shown that pharmacological inhibition of β-adrenergic receptors did not avert 
HR rise after 2-weeks of high altitude (HA) exposure (Hughson et al. 1994), implying the 
cause to be sustained PSNS withdrawal. Nevertheless, administration of muscarinic receptor 
antagonists increased HR after 9 weeks of HA exposure, suggesting increased PSNS activity 
(Boushel et al. 2001). It was speculated that these inconsistencies may be related to 
methodological considerations; particularly the inhibition of different receptor types, that 
merely one receptor was targeted per study, different subject groups and different exposure 
durations.  
The readers were then led to the main objective of the study, which detailed how the authors 
would build upon existing knowledge by isolating the relative contributions of the SNS and 
PSNS, as well as the potential non-autonomic mechanisms contributing to increased HR in 
chronic hypoxia. The authors proposed that the increased HR associated with chronic 
hypoxia could be explained by a combination of both sympathoactivation and 
parasympathetic withdrawal and also hypothesised that a full cardiac autonomic blockade 
would eliminate HA-induced increases in HR.  
 
In order to address this, seven male participants spent 4 weeks at 3454 m altitude, where all 
measurements were taken the week before ascent at sea level (SL) and over 2 days during the 
15-18 days at HA. A number of haemodynamic parameters were analysed, alongside venous 
noradrenaline and arterial blood analysis. Measurements of such parameters were taken on 
the first day with no receptor inhibition being administered (CONT) and again following 
administration of glycopyrrolate (GLYC). On day two the measurements were taken after 
administration of propranolol (PROP), and again after additional administration of GLYC, 
forming the PROP+GLYC condition. Statistically a mixed model approach was employed to 
assess the effect of HA within the different drug conditions. 
 
The results of this study showed a significant increase in HR from SL to HA during CONT 
(9.7 ± 7.9 bpm, P=0.007) and PROP (7.6 ± 4.0 bpm, P<0.001), but not during GLYC (2.3 ± 
6.0 beats min−1, P=0.28) and PROP+GLYC treatment (2.3 ± 5.4 beats min−1, P=0.25). They 
also revealed the effect of HA on cardiac stroke volume and cardiac output depended on the 
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type of receptor inhibition. Specifically stroke volume did not change significantly at HA 
during CONT treatment (–0.2 ± 19.2 ml, P=0.8) whereas a reduction was observed following 
PROP (–23.0 ± 13.4 ml, P<0.001), GLYC (–12.8 ± 11.9 ml, P=0.01) and PROP+GLYC 
treatments (–25.7 ± 16.1 ml, P<0.001). Cardiac output increased at HA during CONT 
treatment (1.1 ± 2.2 l min−1, P=0.2) but was reduced following PROP (0.8 ± 0.8 l min−1, 
P=0.02), GLYC (1.1 ± 1.1 l min−1, P=0.02) and PROP+GLYC (2.0 ± 1.5 l min−1, P=0.002). 
Furthermore venous noradrenaline rose by 245% from day 2 at HA to day 10 (1.1 nmol ± 0.5 
vs. 2.7 ± 1.5 nmol l-1, P=0.03), and by a further 11% at day 26 (3.0 ± 1.2 nmol l−1, P=0.007). 
Mean arterial blood pressure (MAP) also increased at HA (P=0.001) however this was 
unaltered by any of the autonomic antagonists.  
These results infer that cardiac parasympathetic withdrawal persists throughout HA 
acclimatisation and comprises the dominating cardioacceleratory mechanism, owing to the 
finding that increased HR was persistent when β-adrenergic, but not when muscarinic 
receptors were inhibited. The authors suggest that this may be the result of a reflex response 
to the activation of pulmonary stretch receptors by enhanced ventilation. The authors also 
suggest that the absence of a HA-induced increase in HR during combined inhibition of β-
adrenergic and muscarinic receptors rules out a relevant contribution of a non-autonomic 
mechanism. 
 
To our knowledge, this is the first study to provide novel findings related to the non-
autonomous mechanism(s) responsible for sustained HR elevation with chronic HA exposure. 
The authors clearly state the research question and employ logical methodologies to tackle it, 
and discuss the findings in a scientifically-backed and concise manner. In general, the 
discussion is well-written, with many references made to previous research, which link with 
the literature they pose in their introduction.  
 
They diligently state their study limitations, namely the small subject number and the lack of 
double—blindness. We came across some alternative critique that we wish to discuss in a 
constructive way, section by section.   
 
The rationale of the drugs used and the fundamental pharmacokinetics have not been defined, 
making it difficult for readers to fully understand the logic. A brief description of each drug’s 
purpose and action would have been useful.  
The authors say that they preserved subjects’ activity levels, but did not elaborate as to 
time/frequency stipulations and also gave no report of baseline levels. This is important to 
understand, as the hemodynamic parameters measured here are highly linked to training 
status, and the results reported may be reflective of that. Similarly, the authors did not 
elaborate on food and beverage consumption; specifically the absence of alcohol and caffeine 
intake in the preceding 24-hour period, likely to affect hemodynamics (Park and Ciffeli 
2013).  
With regards to the results, it is suggested that figure 2 graphs be slightly more elaborate; 
perhaps by adding coloured individual differences in order to distinguish between subject 
responses.  
Systolic blood pressure forms the majority of the contribution to the MAP calculation, yet 
there was no mention of it; it would have been valuable to see to what extent this changed, 
and any change to the relationship with diastolic blood pressure.  During the discussion the 
authors assume an absence of a decrease in stroke volume (SV) during the control is a false 
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negative. However, little attempt is made at addressing the methodological limitation in 
which SV was obtained as a derived measure. 
We believe that there could have been a clearer rationale as to the study objectives; hence we 
did not fully identify the meaningfulness behind it. It is clearly stated that HR is still elevated 
with chronic exposure to HA, but the authors do not explain why this is an issue, or what the 
clinical relevance is. We believe we are missing the ―so what?‖ aspect, with regards to 
chronic HA exposure and elevated HR. There is still no mention of the issues associated with 
this, and what, if any, the applications may be.  Does it matter that HR is elevated with 
chronic HA exposure? May this link to pathologies associated with HA, for instance by 
contributing to increasing pulmonary artery pressure that may in turn increase risk of 
pulmonary odema?  A more elaborate discussion on this aspect would have been beneficial in 
understanding the broader scientific relevance.  
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